Evaluation of lymphocyte therapy effects on treatment of women with unexplained Recurrent Spontaneous Abortion (RSA)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201126049497N2

Enrollment

Registered

2024-07-11

Start date

2024-09-22

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent spontaneous abortion.

Interventions

Intervention group: Miscarriage patients.

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: The age range from 18 to 35 years The presence of repeated miscarriages with unknown reasons and the possibility of immunological reasons Presence of APCA antibody percentage lower than 5%

Exclusion criteria

Exclusion criteria: Presence of abortion with known non-immunological causes Presence of APCA antibody percentage higher than 5%

Design outcomes

Primary

Measure	Time frame
No abortion and successful pregnancy. Timepoint: Before the intervention and after the intervention. Method of measurement: The number of births resulting in the birth of a healthy baby.	—

Secondary

Measure	Time frame
APCA antibody percentage. Timepoint: At intervals of 3 weeks and up to 3 times. Method of measurement: complement-dependent cytotoxicity method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVajihe Hazari

Birjand University of Medical Sciences

dr.vhazari@gmail.com+98 56 3243 6691

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026